DK1817079T3 - Behandling af inflammationer - Google Patents
Behandling af inflammationerInfo
- Publication number
- DK1817079T3 DK1817079T3 DK05813139T DK05813139T DK1817079T3 DK 1817079 T3 DK1817079 T3 DK 1817079T3 DK 05813139 T DK05813139 T DK 05813139T DK 05813139 T DK05813139 T DK 05813139T DK 1817079 T3 DK1817079 T3 DK 1817079T3
- Authority
- DK
- Denmark
- Prior art keywords
- a3ar
- inflammatory state
- subject
- level
- wbc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rehabilitation Therapy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63219804P | 2004-12-02 | 2004-12-02 | |
| US65771805P | 2005-03-03 | 2005-03-03 | |
| PCT/IL2005/001280 WO2006059328A1 (en) | 2004-12-02 | 2005-11-30 | Treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1817079T3 true DK1817079T3 (da) | 2008-11-17 |
Family
ID=35708899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05813139T DK1817079T3 (da) | 2004-12-02 | 2005-11-30 | Behandling af inflammationer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20080056992A1 (da) |
| EP (2) | EP1817079B1 (da) |
| JP (2) | JP4842964B2 (da) |
| KR (2) | KR20070100261A (da) |
| AT (2) | ATE402739T1 (da) |
| AU (2) | AU2005310873B2 (da) |
| BR (2) | BRPI0518777A2 (da) |
| CA (2) | CA2586773C (da) |
| DE (2) | DE602005015135D1 (da) |
| DK (1) | DK1817079T3 (da) |
| ES (2) | ES2327435T3 (da) |
| MX (2) | MX2007006500A (da) |
| WO (2) | WO2006059328A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007043054A1 (en) * | 2005-10-12 | 2007-04-19 | Can-Fite Biopharma Ltd. | Treatment and monitoring disease state of liver cancer |
| KR101101252B1 (ko) * | 2005-11-30 | 2012-01-04 | 캔-파이트 바이오파마 리미티드 | 골관절염 치료를 위한 ａ3 아데노신 수용체 아고니스트의용도 |
| US20080183101A1 (en) * | 2006-08-17 | 2008-07-31 | Jonathan Richard Stonehouse | Salivary analysis |
| WO2008023362A2 (en) * | 2006-08-21 | 2008-02-28 | Can-Fite Biopharma Ltd. | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer |
| WO2008056361A1 (en) * | 2006-11-09 | 2008-05-15 | Can-Fite Biopharma Ltd. | A biological marker for psoriasis |
| ES2641190T3 (es) | 2007-03-14 | 2017-11-08 | Can-Fite Biopharma Ltd. | Procedimiento de síntesis de IB-MECA |
| IL200753A (en) * | 2009-09-06 | 2015-06-30 | Can Fite Biopharma Ltd | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis |
| EP2542242A1 (en) * | 2010-03-03 | 2013-01-09 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | A3ar agonists for the treatment of uveitis |
| WO2011158904A1 (ja) * | 2010-06-18 | 2011-12-22 | 株式会社林原生物化学研究所 | アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤 |
| KR102095284B1 (ko) | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985005031A1 (en) | 1984-05-09 | 1985-11-21 | The Australian National University | A method for the modulation of the immune response |
| AU5182500A (en) | 1996-08-01 | 2000-10-26 | Kennedy Institute Of Rheumatology, The | Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease |
| AU5696198A (en) | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
| US20020179549A1 (en) * | 2001-06-04 | 2002-12-05 | Chris Felcman | System and method for mounting a keyboard and display assembly in a 1U rack space |
| JP2004135657A (ja) * | 2002-08-21 | 2004-05-13 | Kyowa Hakko Kogyo Co Ltd | ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物 |
| JP2006503564A (ja) * | 2002-10-21 | 2006-02-02 | カン−フィテ・バイオファーマ・リミテッド | 治療学的処置のための診断マーカー |
| US20040229246A1 (en) * | 2002-10-21 | 2004-11-18 | Can-Fite Biopharam Ltd. | Diagnostic markers for therapeutic treatment |
| US20040137477A1 (en) * | 2002-10-22 | 2004-07-15 | Can-Fite Biopharma, Ltd. | A3AR as a marker for a diseased state |
| WO2004045627A1 (en) * | 2002-11-19 | 2004-06-03 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
| WO2004086034A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3) |
| US20050074451A1 (en) | 2003-06-25 | 2005-04-07 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US7465715B2 (en) | 2003-12-29 | 2008-12-16 | Can-Fite Biopharma, Ltd. | Method for treatment of multiple sclerosis |
-
2005
- 2005-11-30 WO PCT/IL2005/001280 patent/WO2006059328A1/en active IP Right Grant
- 2005-11-30 DE DE602005015135T patent/DE602005015135D1/de active Active
- 2005-11-30 EP EP05813139A patent/EP1817079B1/en not_active Not-in-force
- 2005-11-30 US US10/565,238 patent/US20080056992A1/en not_active Abandoned
- 2005-11-30 WO PCT/IL2005/001279 patent/WO2006059327A1/en active Application Filing
- 2005-11-30 JP JP2007544007A patent/JP4842964B2/ja active Active
- 2005-11-30 KR KR1020077014957A patent/KR20070100261A/ko not_active Application Discontinuation
- 2005-11-30 JP JP2007544008A patent/JP2008521883A/ja not_active Withdrawn
- 2005-11-30 AU AU2005310873A patent/AU2005310873B2/en active Active
- 2005-11-30 MX MX2007006500A patent/MX2007006500A/es active IP Right Grant
- 2005-11-30 KR KR1020077014958A patent/KR20070090222A/ko not_active Application Discontinuation
- 2005-11-30 DK DK05813139T patent/DK1817079T3/da active
- 2005-11-30 CA CA2586773A patent/CA2586773C/en active Active
- 2005-11-30 ES ES05812529T patent/ES2327435T3/es active Active
- 2005-11-30 AU AU2005310874A patent/AU2005310874B2/en not_active Ceased
- 2005-11-30 EP EP05812529A patent/EP1817589B1/en active Active
- 2005-11-30 MX MX2007006501A patent/MX2007006501A/es active IP Right Grant
- 2005-11-30 CA CA002586774A patent/CA2586774A1/en not_active Abandoned
- 2005-11-30 AT AT05813139T patent/ATE402739T1/de not_active IP Right Cessation
- 2005-11-30 BR BRPI0518777-0A patent/BRPI0518777A2/pt not_active IP Right Cessation
- 2005-11-30 DE DE602005008639T patent/DE602005008639D1/de not_active Expired - Fee Related
- 2005-11-30 BR BRPI0518795-8A patent/BRPI0518795A2/pt not_active Application Discontinuation
- 2005-11-30 AT AT05812529T patent/ATE434762T1/de not_active IP Right Cessation
- 2005-11-30 ES ES05813139T patent/ES2309817T3/es active Active
-
2010
- 2010-06-21 US US12/819,945 patent/US8541182B2/en active Active
-
2013
- 2013-08-22 US US13/973,595 patent/US20130345163A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0518795A2 (pt) | 2008-12-09 |
| ES2327435T3 (es) | 2009-10-29 |
| US8541182B2 (en) | 2013-09-24 |
| EP1817079A1 (en) | 2007-08-15 |
| JP4842964B2 (ja) | 2011-12-21 |
| AU2005310874A1 (en) | 2006-06-08 |
| ATE402739T1 (de) | 2008-08-15 |
| WO2006059328A1 (en) | 2006-06-08 |
| ATE434762T1 (de) | 2009-07-15 |
| DE602005008639D1 (de) | 2008-09-11 |
| AU2005310873B2 (en) | 2008-11-27 |
| MX2007006501A (es) | 2007-07-13 |
| JP2008521883A (ja) | 2008-06-26 |
| KR20070100261A (ko) | 2007-10-10 |
| EP1817079B1 (en) | 2008-07-30 |
| WO2006059327A1 (en) | 2006-06-08 |
| EP1817589A1 (en) | 2007-08-15 |
| CA2586773A1 (en) | 2006-06-08 |
| AU2005310874B2 (en) | 2008-11-27 |
| ES2309817T3 (es) | 2008-12-16 |
| US20130345163A1 (en) | 2013-12-26 |
| JP2008522182A (ja) | 2008-06-26 |
| KR20070090222A (ko) | 2007-09-05 |
| EP1817589B1 (en) | 2009-06-24 |
| US20100256084A1 (en) | 2010-10-07 |
| BRPI0518777A2 (pt) | 2008-12-09 |
| CA2586774A1 (en) | 2006-06-08 |
| AU2005310873A1 (en) | 2006-06-08 |
| DE602005015135D1 (de) | 2009-08-06 |
| CA2586773C (en) | 2018-03-27 |
| US20080056992A1 (en) | 2008-03-06 |
| MX2007006500A (es) | 2007-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1817079T3 (da) | Behandling af inflammationer | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| EA202091230A3 (ru) | Антагонисты активин-actrii и их применения для повышения уровней эритроцитов | |
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
| WO2007123976A3 (en) | Antibody profiling for determination of patient responsiveness | |
| RU2011105466A (ru) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях | |
| ATE548050T1 (de) | Diagnoseverfahren | |
| WO2013022953A3 (en) | Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof | |
| BR112012031166A2 (pt) | compensação baseada eminclinação incluindo sinais de saída secundários | |
| DE602005023725D1 (de) | Diagnose und überwachung von entzündlichen krankheiten mittels messung der zusätzlichen komponenten von leukozyten | |
| WO2010025393A3 (en) | Protein biomarkers and methods for diagnosing kawasaki disease | |
| BRPI0516242A (pt) | compostos tieno-pirimidina tendo atividade fungicida | |
| EA201390543A1 (ru) | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат | |
| WO2007044622A8 (en) | Use of mif and mif pathway agonists | |
| FR2900936B1 (fr) | Procede et methodes de detection de la maladie d'alzheimer | |
| CY1111356T1 (el) | Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl | |
| WO2007024752A3 (en) | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders | |
| EA201500526A1 (ru) | Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения | |
| NZ599373A (en) | Biomarkers for predicting rapid response to hcv treatment | |
| Reudelhuber | Where hypertension happens | |
| ME01128B (me) | Upotreba 7-hlor-n,n,5-trimetil-4-okso-3-fenil- 3,5-dihidro-4h-piridazino [4,5-b]indol-1-acetamida kao biomarkera za nivoe perifernih benzodiazepinskih receptora | |
| WO2011113942A3 (en) | Method for predicting the responsiveness to chemotherapy | |
| DE602005014151D1 (de) | Herzstimulationsvorrichtung | |
| EA201001340A1 (ru) | Улучшенный аналитический способ для определения латентного гепатита с, его применения и соответствующий диагностический набор |